BioWorld

Sep. 4, 2008

View Archived Issues

Pfizer to Pay Medivation $225M Up Front in Dimebon Deal

Drugmaker Pfizer Inc. will pay a hefty $225 million up front to Medivation Inc. in a deal to co-develop and market Dimebon, the biotech company's experimental drug for Alzheimer's and Huntington's disease. (BioWorld Today) Read More

More Government Funding: SIGA Adds $55M, Emergent Gets $24M

Read More

BIO Sets Sights on 2009 for FOBs, Patent Reform

Read More

NewCo News: Wintherix Uses Pfizer Library to Find Wnt Inhibitors for Cancer

Read More

Osprey Raises $11M to Move Kidney Drug into the Clinic

Read More

Other News To Note

Read More

Clinic Roundup

Read More